PEOPLE TAKING GLP-1S have a reduced risk of heart attacks, strokes, and death from cardiovascular disease, according to a ...

Approved for use by diabetics to control blood sugar, liraglutide has also evidenced an ability to slow cognitive decline in a Phase 2b clinical trial, and reduce shrinkage of those areas of the brain ...

Novo Nordisk has won a Committee for Medicinal Products for Human Use (CHMP) endorsement for a higher-dose version of its diabetes drug liraglutide that can be used to treat obesity. The Danish ...

Positive results in a recent animal study strongly supports first-ever human investigation for DehydraTECH-liraglutide in an oral capsule format KELOWNA, BC / ACCESSWIRE / January 15, 2025 / Lexaria B ...

It's not just celebrities and TikTok creators jumping on the weight loss drug hype - more than 500,000 people in the UK are ...

Heavy drinkers who were ­taking weight-loss jabs in a Dublin clinic significantly reduced their ­alcohol intake down from 12 ...

The study used the company's older GLP-1 agonist therapy Saxenda (liraglutide), which requires a daily injection, rather than its top-selling once-weekly obesity drug Wegovy (semaglutide), and ...

Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

A dozen GLP-1 receptor agonists and coagonists demonstrated effectiveness for weight loss in adults with obesity and without ...

Marketed as Ozempic, Wegovy or Saxenda, these drugs are administered via a weekly injection that mimics GLP-1 - a hormone ...

MailOnline has crunched the full data for all 296 authorities into an interactive map. A searchable chart also shows how ...